Nothing new under the sun: parallel importers must still prove that it is objectively necessary to replace the original package of medicinal products
This post perhaps is a bit off topic since it concerns parallel imports and trademark rights. Nevertheless it could be interesting for the readers since it relates to the the pharma industry. Background It is well established EU case law that a parallel importer of medicinal products may only replace the original package if it…